Purine analogues in the management of lymphoproliferative diseases

Clinical Oncology

Volumn 8, Issue 5, 1996, Pages 289-296

  Johnson, S A ^a  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

Cladribine; Fludarabine; Lymphoproliferative disorders; Pentostatin

Indexed keywords

CLADRIBINE; FLUDARABINE; PENTOSTATIN; PURINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GRAFT VERSUS HOST REACTION; HAIRY CELL LEUKEMIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SKIN LYMPHOMA; T CELL LYMPHOMA; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0029801444     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(05)80714-9     Document Type: Review

References (107)

1. Seto S, Carrera CJ, Kubota M et al. Mechanism of deoxyadenosine and 2-chlorodoxyadenosine toxicity to non dividing human lymphocytes. J Clin Invest 1985;75:377-83.
2. Robertson LE, Chubb S, Meyn RE et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoradenine. Blood 1993;81:143-50.
3. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine: a mechanism of toxicity. J Biol Chem 1990;265:16617-25.
4. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993;11:116-24.
5. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol 1990;17 Suppl 8:3-17.
6. Gregoire V, Hunter N, Milas L, et al. Potentiation of radiation-induced regrowth delay in murine tumours by fludarabine. Cancer Res 1994;54:468-74.
7. Le Page GA, Worth LS, Kimball AP. Enhancement of the antitumor activity of arabinofuranosyladenine by 2-deoxycoformycin. Cancer Res 1976;36:1481-5.
8. Smyth JF, Paine RM, Jackman AL, et al. The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Chemother Pharmacol 1980;5:93-101.
9. Major PP, Agarwal RP, Kufe DW. Deoxycoformycin: Neurological toxicity. Cancer Chemother Pharmacol 1981;5:193-6.
10. Latham B, Diehl V, Clark GM, et al. Cytotoxic activity of 9-βarabinofuranosyl-2-fluoroadenine in a human tumour cloning system. Eur J Cancer Clin Oncol 1988;24:1891-5.
11. Hutton JJ, Von Hoff DD, Kuhn J, et al. Phase I clinical investigation of 9-βD-arabinofuranosyl-2-fluoroadenine-5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 1984;44:4183-6.
12. Carson DA, Wasson B, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983;62:737-43.
13. Liliemark J, Albertoni F, Hassan M, et al. On the bioavailability of oral and subcutaneous 2-deoxyadenosine in humans: Alternative routes of administration. J Clin Oncol 1992;10:1514-8.
14. Prentice HG, Ganeshaguru K, Bradstock KF, et al. Remission induction with adenosine deaminase inhibitor 2-deoxycoformycin in Thy-lymphoblastic leukaemia. Lancet 1980;ii:170-2.
15. Grever MR, Coleman MS, Gray DP, et al. Definition of safe, effective dosing regimen of 2′-deoxycoformycin with biochemical investigation. Cancer Treat Symp 1984;2:43-9.
16. Spriggs DR, Stopa E, Mayer RJ, et al. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res 1986;46:5953-8.
17. Beutler E, Piro LD, Saven A, et al. 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymphoma 1991;5:1-8.
18. Cassileth PA, Cheuvart B, Spiers ASD, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 1991;9:243-6.
19. Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 1994;84:4061-3.
20. Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117-21.
21. Filleul B, Delannoy A, Ferrant A, et al. A single course of 2-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 1994;8:1153-6.
22. Kantarjian HM, Schachner J, Keating MJ. Fludarabine therapy in hairy cell leukemia. Cancer 1991;67:1291-3.
23. Grever M, Kopecky K, Founcar MK, et al. Randomised omparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An Intergroup study. J Clin Oncol 1995;13:974-82.
24. Saven A, Piro L. Newer purine analogues for the treatment of hairy cell leukemia. N Engl J Med 1994;330:691-7.
25. Saven A, Kantor RA, Kosty M, et al. Randomised trial of pentoxifylline for 2-chlorodeoxyadenosine induced neutropenic fever in hairy cell leukemia patients. Proc ASCO 1994;13:A1029.
26. Juliusson G, Lenkei R, Tjonnfjord G, et al. Neutropenic fever following cladribine therapy for symptomatic hairy cell leukemia: Predictive factors and effects of granulocyte-macrophage colony-stimulating factor. Ann Oncol 1995; 6:371-5.
27. Montserrat E, Rozman C. Chronic lymphocytic leukaemia prognostic factors and natural history. Baillieres Clin Haematol 1993;6:849-66.
28. Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988;30:457-9.
29. Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993;81:2878-84.
30. Sorensen JM, Vena D, Fallavollita A, et al. Treatment of refractory chronic lymphocytic leukemia (CLL) with fludarabine monophosphate (FAMP) under the Group C protocol. Proc ASCO 1992;11:A867.
31. The French Co-operative Group on CLL, Johnson S, Smith AG, et al. Fludarabine versus cyclophosphamide, doxorubicin, prednisolone (CAP) for the treatment of advanced stage chronic lymphocytic leukaemia - results of a multicentre prospective randomised trial. Lancet. In press.
32. Rai KR, Petersen B, Kolitz J, et al. Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL): A randomised Inter-group study. Proc Am Soc Hematol 1995;86:A2414.
33. Piro LD, Carrera CJ, Beutler E, et al. 2-Chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988;72:1069-73.
34. Saven A, Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1991;5 Suppl:133-8.
35. Juliusson G, Liliemark J. High complete remission rate from 2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993; 11:679-89.
36. Juliusson G, Christiansen I, Mork-Hansen M, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol. In press.
37. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: A phase II trial of Cancer and Leukemia Group B. J Clin Oncol 1989;7:433-8.
38. Ho AD, Thaler J, Stryckmans P, et al. Pentostatin in refractory chronic lymphocytic leukemia: A Phase II trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 1990;82:1416-20.
39. Richardson DS, Johnson SA, Hopkins JA, et al. Absence of minimal residual disease detectable by FACS, Southern blot or PCR in patients with chronic lymphocytic leukaemia treated with fludarabine. Acta Oncol 1994;33:627-30.
40. Cull G, Richardson DS, Howe DJ, et al. Molecular complete response in a patient with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine. Acta Oncol 1995; 34:536-7.
41. Juliusson G, Liliemark J. Re-treatment of chronic lymphocytic leukaemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: No acquired resistance. Leuk Lymphoma 1994;13:75-80.
42. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992;327:1056-61.
43. Delannoy A, Hanique G, Ferrant A. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993;328:812.
44. Saven A, Lemon RH, Piro LD. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993;328:812-3.
45. O'Brien S, Kantarjian H, Estey E, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994;330:319-22.
46. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisolone therapy in 264 patients with chronic lymphocytic leukemia with multi-variate analysis-derived prognostic model for response to treatment. Blood 1993;82:1695-700.
47. Robertson LE, O'Brien S, Kantarjian H, et al. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 1995;9:943-5.
48. Gandhi V, Robertson LE, Keating MJ, et al. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukaemia: Clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol 1994;34:30-6.
49. Robertson LE, Kantarjian H, O'Brien S, et al. Cisplatin, fludarabine and ara C(PFA): A regime for advanced fludarabine refractory chronic lymphocytic leukamia (CLL). Proc ASCO 1993;12:A1014.
50. Weiss M, Spiess T, Berman E, et al. Concomitant adminstration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 1994;8:1290-3.
51. Elias L, Stock-Novak D, Head DR, et al. A Phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Leukemia 1993;7:361-5.
52. Leiby JM, Snider KM, Kraut EH, et al. Phase II trial of 9-β-D-arabinofuranosyl-2-fluoroadenine-5′-monophosphate in non-Hodgkin's lymphoma: Prospective comparison of response with deoxycytidine kinase activity. Cancer Res 1987;47:2719-22.
53. Redman JR, Cabanillas F, Velasquez WS, et al. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 1992;10:790-4.
54. Whelan JS, Davis CL, Rule S, et al. Fludarabine phosphate for the treatment of low-grade lymphoid malignancy. Br J Cancer 1991;64:120-3.
55. Hochster HS, Kim K, Green MD, et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Co-operative Oncology Group study. J Clin Oncol 1992;10:28-32.
56. Solal-Celigny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first line treatment in patients with advanced follicular lymphoma: A multicenter study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996;14:514-9.
57. Betticher DC, Fey MF, Von Rohr A, et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CdA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 1994;5:57-64.
58. Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphoma. J Clin Oncol 1992;10:371-7.
59. Hickish T, Serafinowski P, Cunningham D, et al. 2′-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer 1993;67:139-43.
60. Hoffman M, Tallman M, Hakimian D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:788-92.
61. Saven A, Emanuele S, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 1995;86:1710-6.
62. Duggan DB, Anderson JR, Dillman R, et al. 2-Deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma: A CALGB Phase II study. Med Pediatr Oncol 1990;18:203-6.
63. Grever MR, Siaw M, Jacob WF, et al. The biochemical and clinical consequences of 2-deoxycoformycin in refractory lymphoproliferative malignancies. Blood 1981;57:406-17.
64. Spiers ASD. Experience with 2′-deoxycoformycin in treatment of refractory leukemias and lymphomas. Cancer Treat Symp 1984;2:51-4.
65. Tobinai K, Shimoyama M, Inoue S, et al. Phase I study of YK-176 (2′-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. Jpn J Clin Oncol 1992;22:164-71.
66. Dearden C, Matutes E, Catovsky D. Deoxycoformycin in the treatment of mature T-cell leukaemias. Br J Cancer 1991;64:903-6.
67. Grever MR, Bisaccia E, Scarborough DA, et al. An investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 1983;61:279-82.
68. Ho AD, Thaler J, Willemze R, et al. Pentostatin (2′-deoxycoformycin) for the treatment of lymphoid neoplasms. Cancer Treat Rev 1990;17:213-5.
69. Cummings FJ, Kim K, Neiman RS, et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 1991;9:565-71.
70. Foss FM, Ihde DC, Breneman DL, et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 1992;10:1907-13.
71. Saven A, Carrera CJ, Carson DA, et al. 2′-Chlorodeoxyadenosine: An active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992;80:587-92.
72. Von Hoff DD, Dahlberg S, Hartstock RJ, et al. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group study. J Natl Cancer Inst 1990;82:1353-5.
73. Foss FM, Ihde DC, Linnoila IR, et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 1994; 12:2051-9.
74. Riddell A, Johnson JE, Rayner HL, et al. Response of Waldenström's macroglobulinaemia to pentostatin (2′-deoxycoformycin). Cancer Treat Rep 1986;70:546-8.
75. Kantarjian H, Alexanian R, Koller CA, et al. Fludarabine therapy in macroglobulinemic lymphoma. Blood 1990; 75:1928-31.
76. Dimopoulos MA, Kantarjian H, Estey E, et al. Treatment of Waldenström macroglobulinemia with 2′-chlorodeoxyadenosine. Ann Intern Med 1993;118:195-8.
77. Delannoy A, Ferrant A, Martiat P, et al. 2-Chlorodeoxyadenosine therapy in Waldenström's macroglobulinaemia. Nouv Rev Fr Hematol 1994;36:317-20.
78. Dimopoulos MA, Weber D, Delasalle KB, et al. Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2′-chlorodeoxyadenosine: Identification of prognostic factors. Ann Oncol 1995;6:49-52.
79. Grever MR, Crowley JJ, Salmon S, et al. Phase II investigation of pentostatin in multiple myeloma: A Southwest Oncology Group Study. J Natl Cancer Inst 1990;82:1778-9.
80. Kraut EH, Crowley JJ, Grever MR, et al. Phase II study of fludarabine phosphate in multiple myeloma: A Southwest Oncology Group study. Invest New Drugs 1990;8:199-200.
81. Delannoy A, Ferrant A, Martiat P, et al. 2′-Chlorodeoxyadenosine and multiple myeloma. Eur J Haematol 1994; 53:181-2.
82. Tefferi A, Witzig TE, Reid JM, et al. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J Clin Oncol 1994;12:569-74.
83. Seymour JF, Grigg A, Szer J, et al. Fludarabine, cisplatin and ara-C: An active regimen in patients with anthracycline-refractory intermediate-grade non-Hodgkin's lymphoma. Proc Am Soc Hematol 1995;86:A209.
84. McLaughlin P, Hagemeister FB, Swan F, et al. Phase I study of the combination of fludarabine, mitoxantrone and dexamethasone in low-grade lymphoma. J Clin Oncol 1994; 12:575-9.
85. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995;13:2431-48.
86. Steis RG, Urba WJ, Kopp WC, et al. Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients. J Natl Cancer Inst 1991;83:1678-9.
87. Wijermans PW, Gerrits WBJ, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993;50:292-6.
88. Seymour JF, Kurzrock R, Freireich EJ, et al. 2′-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994;83:2906-11.
89. Bergmann L, Fenchel K, Jahn B, et al. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukaemia. Ann Oncol 1993;4:371-5.
90. Byrd JC, Hargis JB, Rester KE, et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: A role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995;49:135-42.
91. Kobayshi K, Vogelzang NJ, O'Brien SM, et al. A Phase I study of intermittent infusion cladribine in patients with solid tumours. Cancer 1994;74:168-73.
92. Weiss GR, Kuhn JG, Rizzo J, et al. A Phase I and pharmacokinetic study of 2′-chlorodeoxyadenosine in patients with solid tumours. Cancer Chemother Pharmacol 1995;35:397-402.
93. Frame JN, Sorensen JM, Quashu N, et al. Tumor lysis syndrome (TLS) in patients receiving fludarabine for chronic lymphocytic leukemia. Proc Am Soc Hematol 1993;82:A139.
94. Dann EJ, Gillis S, Polliack A, et al. Brief report: Tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia. N Engl J Med 1993;329:1547-8
95. Woodcock BE. Cytopenia and fludarabine. Lancet 1993;343:1049.
96. Leporrier M, Reman O, Troussard X. Pure red cell aplasia with fludarabine for chronic lymphocytic leukaemia. Lancet 1993;342:555.
97. Jaccard A, Oksenhendler E, Clauvel JP. Cytopenia and fludarabine. Lancet 1993;342:1049-50.
98. Delannoy A, Martiat P, Gala JL, et al. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995;9:1130-5.
99. Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995;91:341-4.
100. Di Raimondo F, Giustolisi R, Cacciola E, et al. Autoimmune hemolytic anaemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 1993;11:63-8.
101. Byrd JC, Hertler AA, Weiss RB, et al. Fatal recurrence of autoimmune haemolytic anaemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anaemia. Ann Oncol 1995;6:300-01.
102. Maung ZT, Wood AC, Jackson GH, et al. Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 1994; 88:649-52.
103. Zulian GB, Roux E, Tiercy JM, et al. Transfusion-associated graft-versus-host disease in a patient treated with cladribine (2-chlorodeoxyadenosine): Demonstration of exogenous DNA in various tissue extracts by PCR analysis. Br J Haematol 1995;89:83-9.
104. Cheson BD, Vena DA, Foss FM, et al. Neurotoxicity of purine analogs: A review. J Clin Oncol 1994;12:2216-28.
105. Cohen RB, Abdallah JM, Gray JR, et al. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 1993;118:114-6.
106. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukaemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granolocyte colony-stimulating factor. J Clin Oncol 1994;12:671-8.
107. Gandhi V, Estey E, Keating MJ, et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic and molecular interactions. Blood 1996;87:256-64.